s-adenosylhomocysteine has been researched along with Coronary-Artery-Disease* in 3 studies
3 other study(ies) available for s-adenosylhomocysteine and Coronary-Artery-Disease
Article | Year |
---|---|
Association between plasma S-adenosylmethionine and risk of mortality in patients with coronary artery disease: A cohort study.
S-adenosylmethionine (SAM) as methyl donors participates in methylation and is converted into S-adenosylhomocysteine (SAH), which is a precursor of homocysteine. Increased plasma SAH and homocysteine are associated with increased risk of cardiovascular disease. However, the relation of plasma SAM with cardiovascular risk is still unclear.. To determine the relation between plasma SAM and risk of mortality among patients with coronary artery disease (CAD).. Baseline plasma SAM concentrations were measured in 1553 patients with CAD from the Guangdong Coronary Artery Disease Cohort between October 2008 and December 2011. Proportional hazards Cox analyses were performed to ascertain associations between SAM and risk of all-cause and cardiovascular mortality.. After a median follow-up of 9.2 (IQR: 8.5-10.2) y, of 1553 participants, 321 had died, including 227 deaths from cardiovascular diseases. Patients in the lowest quartile of SAM concentrations had a higher risk of all-cause death (HR, 1.59; 95% CI: 1.14, 2.21) and cardiovascular death (HR, 2.14; 95% CI: 1.41, 3.27) than those in the highest quartile in multivariable adjusted analysis. Each 1-SD decrease in the SAM concentration remained associated with a 42% greater risk of total death (HR, 1.42; 95% CI: 1.23, 1.64) and a 66% higher risk of cardiovascular death (HR, 1.66; 95% CI: 1.37, 2.01) after fully adjusting for other cardiovascular risk factors. Furthermore, each 1-SD decrease in plasma SAM/SAH ratio, as the methylation index, was also inversely associated with the risk of all-cause (HR, 1.80; 95% CI: 1.42, 2.29) and cardiovascular mortality (HR, 1.68; 95% CI: 1.29, 2.19) in fully adjusted analyses.. Our data show a significant inverse relation between plasma SAM and risk of mortality in patients with CAD after adjustment for homocysteine, SAH, and other cardiovascular disease risk factors. Topics: Aged; Cohort Studies; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Prospective Studies; S-Adenosylhomocysteine; S-Adenosylmethionine | 2021 |
Inhibition of S-Adenosylhomocysteine Hydrolase Induces Endothelial Dysfunction via Epigenetic Regulation of p66shc-Mediated Oxidative Stress Pathway.
Elevated levels of S-adenosylhomocysteine (SAH), the precursor of homocysteine, are positively associated with the risk of cardiovascular disease and with the development and progression of atherosclerosis. However, the role of SAH in endothelial dysfunction is unclear.. Apolipoprotein E-deficient ( apoE. Plasma SAH levels were increased in SAHH. Our findings indicate that inhibition of SAHH results in elevated plasma SAH levels and induces endothelial dysfunction via epigenetic upregulation of the p66shc-mediated oxidative stress pathway. Our study provides novel molecular insight into mechanisms of SAH-associated endothelial injury that may contribute to the development of atherosclerosis.. URL: https://www.clinicaltrials.gov . Unique identifier: NCT03345927. Topics: Adenosine; Adenosylhomocysteinase; Aged; Animals; Atherosclerosis; Coronary Artery Disease; Disease Models, Animal; DNA Methylation; Endothelium, Vascular; Epigenesis, Genetic; Female; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Knockout, ApoE; Middle Aged; Oxidative Stress; RNA, Small Interfering; S-Adenosylhomocysteine; Signal Transduction; Src Homology 2 Domain-Containing, Transforming Protein 1 | 2019 |
The relationship between S-adenosylhomocysteine and coronary artery lesions: A case control study.
The role of homocysteine (Hcy) in the pathogenesis of coronary artery disease (CAD) is controversial, as decreased Hcy levels have not demonstrated consistent clinical benefits. Recent studies propose that S-adenosylhomocysteine (SAH), and not Hcy, plays a role in cardiovascular disease (CVD). We aimed to assess the relationship between plasma SAH and coronary artery lesions. Participants (n=160; aged 40-80years) with chest pain and suspected CAD underwent coronary angiography (CAG) for assessment of coronary artery stenosis, and were assigned to either the atherosclerosis (AS) or CAD group. Plasma SAH and S-adenosylmethionine (SAM) concentrations were measured and the association between coronary artery lesions and SAH was assessed. SAH levels were significantly higher in the CAD group (23.09±2.4nmol/L) than in the AS group (19.2±1.5nmol/L). While the AS group had higher values for SAM/SAH (5.1±0.7 vs. 4.1±1.1), levels of SAM, Hcy, folate, and vitamin B12 were similar in the two groups. Coronary artery lesions were associated with SAH (β=11.8 [95% CI: 5.88, 17.7, P<0.05]. Plasma SAH concentrations are independently associated with coronary artery lesions among patients undergoing coronary angiography. Plasma SAH might be a novel biomarker for the early clinical identification of CVD. Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Chromatography, High Pressure Liquid; Coronary Artery Disease; Female; Humans; Male; Middle Aged; S-Adenosylhomocysteine; S-Adenosylmethionine | 2017 |